Related Experiment Video
Updated: Sep 15, 2025
05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.2K
FACTORS INFLUENCING THE NUMBER OF ANTI-VEGF INJECTIONS IN MYOPIC CHOROIDAL NEOVASCULARIZATION: A Multicenter Study
Niccolò Castellino1, Giovanni Rubegni2, Max Brinkmann3
1Department of Ophthalmology, University of Catania, Catania, Italy.
Retina (Philadelphia, Pa.)
|July 14, 2025
Summary
Poorer baseline visual acuity and higher central macular thickness in myopic choroidal neovascularization (mCNV) predict the need for more anti-VEGF injections. Clinical features differ between patients requiring few versus many injections.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Neovascularization
Background:
- Myopic choroidal neovascularization (mCNV) is a leading cause of vision loss in high myopia.
- Anti-VEGF therapy is the standard treatment, but the number of injections varies.
- Identifying factors influencing treatment response is crucial for patient management.
Purpose of the Study:
- To determine factors affecting the number of anti-VEGF injections needed for mCNV.
- To identify clinical features of patients requiring fewer injections for mCNV inactivation.
Main Methods:
- Retrospective study of 86 treatment-naïve mCNV eyes over 12 months.
- Treatment involved pro re nata (as needed) anti-VEGF injections.
- Ophthalmic evaluations, OCT, and OCTA were performed at baseline and 12 months.
Main Results:
- Mean injections: 4.28±2.17 over 12 months.
- Baseline Central Macular Thickness (CMT) and Best-Corrected Visual Acuity (BCVA) influenced injection number.
- Subretinal fibrosis and final BCVA were final predictors of injection count.
Conclusions:
- Higher baseline CMT and poorer baseline BCVA correlate with increased injection needs in mCNV.
- Distinct OCT, OCTA, and clinical differences exist between patients needing few vs. many injections.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
579
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
579
01:28Angle Closure Glaucoma: Treatment
697
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
697
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K